98%
921
2 minutes
20
Micron sized, lipid stabilized bubbles of gas are of interest as contrast agents for ultra-sound (US) imaging and increasingly as delivery vehicles for targeted, triggered, therapeutic delivery. Microfluidics provides a reproducible means for microbubble production and surface functionalisation. In this study, microbubbles are generated on chip using flow-focussing microfluidic devices that combine streams of gas and liquid through a nozzle a few microns wide and then subjecting the two phases to a downstream pressure drop. While microfluidics has successfully demonstrated the generation of monodisperse bubble populations, these approaches inherently produce low bubble counts. We introduce a new micro-spray flow regime that generates consistently high bubble concentrations that are more clinically relevant compared to traditional monodisperse bubble populations. Final bubble concentrations produced by the micro-spray regime were up to 10(10) bubbles mL(-1). The technique is shown to be highly reproducible and by using multiplexed chip arrays, the time taken to produce one millilitre of sample containing 10(10) bubbles mL(-1) was ∼10 min. Further, we also demonstrate that it is possible to attach liposomes, loaded with quantum dots (QDs) or fluorescein, in a single step during MBs formation.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1039/c2lc40634a | DOI Listing |
J Control Release
September 2025
Department of Ultrasound, China-Japan Friendship Hospital, Beijing 100029, China; National Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine, Chinese Academy of
Anaplastic thyroid cancer (ATC) is the most aggressive form of thyroid malignancy and currently lacks effective treatment options. While anti-PD1 therapy has shown remarkable clinical results in some cases, only a subset of ATC patients responds to it. Eganelisib (IPI549), a highly selective PI3Kγ inhibitor, can alleviate the tumor immunosuppressive state by reducing the proportion of M2-like tumor associated macrophages, partially overcoming patient resistance to anti-PD1 therapy and synergizing with its efficacy.
View Article and Find Full Text PDFUltrason Sonochem
August 2025
Université Paris-Saclay, CEA, CNRS, Inserm, BioMaps, Service Hospitalier Frédéric Joliot, Orsay 91401, France. Electronic address:
Microbubble-mediated focused ultrasound is a promising strategy for transient and localized blood-brain barrier (BBB) permeabilization, enabling drug delivery to the brain. Optimizing microbubble stability and acoustic response is essential to maximize treatment efficiency and minimize potential damage. This study introduces an innovative microbubble formulation with a phospholipid-fluoropolymer shell (LIP-POL), designed to enhance circulation persistence while maintaining a low cavitation threshold.
View Article and Find Full Text PDFMater Today Bio
October 2025
Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, China.
Despite the transformative clinical impact of programmed cell death ligand 1/programmed death 1 (PD-1/PD-L1) blockade in hepatocellular carcinoma (HCC), therapeutic efficacy remains limited by the tumor immunosuppressive microenvironment (TIME), with objective response rates persistently below 20 %. To address this critical clinical challenge, we engineered ultrasound (US)-responsive lipid nanobubbles (NBs) co-encapsulating microRNA (miR)-195-5p and shikonin (SK) (designated miR-195-5p/SK-NBs), a dual-functional platform designed to synergize PD-L1 suppression with immunogenic cell death (ICD). The NBs exhibited tumor-selective accumulation through passive and active targeting mechanisms while maintaining biosafety.
View Article and Find Full Text PDFLiver Cancer
August 2025
Senior Department of Oncology, The Fifth Medical Centre of PLA General Hospital, Beijing, China.
Introduction: It is challenging to diagnose liver masses in the context of a rough liver background using computed tomography and magnetic resonance imaging. Perfluorobutane CEUS microbubble, an ultrasound (US) contrast agent, has a unique phase called the Kupffer phase. This study aimed to explore whether the diagnostic ability of Kupffer-CEUS is affected by the rough liver background.
View Article and Find Full Text PDFPharmacol Res
September 2025
Institute for Experimental Molecular Imaging, RWTH Aachen University Hospital, Forckenbeckstraße 55, Aachen 52070, Germany. Electronic address:
Microbubble-assisted ultrasound can improve the delivery of drugs to tumors by temporarily opening biological barriers, a process commonly referred to as sonopermeation. The type of microbubbles plays a key role in this context, with size distribution and the associated degree of polydispersity being important determinants of treatment efficiency, as a broad size distribution makes it difficult to control the induced effects. Poly(butyl cyanoacrylate) (PBCA) microbubbles have been shown to be suitable for sonopermeation applications due to their narrow, tunable size distribution and unique acoustic response profile.
View Article and Find Full Text PDF